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Multivalency plays a major role in biological processes and particularly in the relationship between
pathogenic microorganisms and their host that involves protein–glycan recognition. These interactions occur
during the first steps of infection, for specific recognition between host and bacteria, but also at different
stages of the immune response. The search for high-affinity ligands for studying such interactions involves
the combination of carbohydrate head groups with different scaffolds and linkers generating multivalent
glycocompounds with controlled spatial and topology parameters. By interfering with pathogen adhesion,
such glycocompounds including glycopolymers, glycoclusters, glycodendrimers and glyconanoparticles have
the potential to improve or replace antibiotic treatments that are now subverted by resistance. Multivalent
glycoconjugates have also been used for stimulating the innate and adaptive immune systems, for example
with carbohydrate-based vaccines. Bacteria present on their surfaces natural multivalent glycoconjugates
such as lipopolysaccharides and S-layers that can also be exploited or targeted in anti-infectious strategies.
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1. Introduction
Carbohydrates constitute the most abundant class of bio-
molecules on Earth. They play roles in the natural world as
diverse as energy storage, molecular recognition for intra-
cellular traﬃcking or interactions between pathogenic micro-
organisms and viruses and the surfaces of mammalian cells.1
The carbohydrates present inside and at the surface of cells
mediate many biological processes that are fundamentally
important for both the healthy and diseased states of living
organisms.2,3 Usually carbohydrates are covalently linked to
other biomolecules such as proteins or lipids. The molecular
and supramolecular scaﬀolds of such glycoconjugates provide
them with a very important property: multivalency.4–7 Indi-
vidual interactions between sugars and proteins are very weak,
however, multiple simultaneous interactions between carbo-
hydrate ligands and their receptors reinforce one-another like
molecular velcro to achieve functionally useful avidities. Recent
advances in carbohydrate microarray technologies8–14 com-
bined with the utilization of freely accessible resources of the
Consortium for Functional Glycomics (http://www.functional
glycomics.org/) have greatly expanded our knowledge of
carbohydrate-binding proteins, and reinforced the importance
of multivalent interactions.15–21 It has become apparent that
the avidities and selectivities of specific interactions are very
dependent on the density of the sugar groups and also the
chemical structure of the linker group to the underlying multi-
valent scaﬀold. Translating this knowledge for the design and
preparation of multivalent glycoconjugates remains a signifi-
cant challenge to diagnose and treat diseases.22–25
Protein–carbohydrate interactions frequently mediate the first
step of the infection process formany pathogens including viruses,
fungi, bacteria, and bacterial toxins.26–29 Therefore, a vast array
of unnatural glycoconjugates (neoglycoconjugates) with various
valencies and spatial arrangement of the ligands have been
constructed to prevent or treat diseases caused by pathogens.
Scaﬀolds based on proteins,30–32 polymers,33–36 calixarenes,37–40
dendrimers,41–45 cyclodextrins,46,47 cyclopeptides,48–50
fullerenes,51,52 gold nanoparticles,53,54 and quantum dots55–57
provide nanoscale materials with anti-adhesive and cell targeting
properties. Such structures that can competitively interfere with
the recognition processes between host cells and pathogens have
the potential to prevent colonisation or even reverse the for-
mation of biofilms. Another alternative to fight pathogens relies
on the utilization of glycoconjugates that can act as vaccines and
immunomodulators. Vaccines have long relied on attenuated
strains of microorganisms as a means of delivering the extra-
cellular carbohydrate antigens. As the cell surface of pathogenic
bacteria and viruses is often covered with unusual carbohydrates,
structurally defined glycoconjugates displaying these structures
are starting to emerge as the vaccines for the future.58,59
Following a lectin-mediated cellular uptake mechanism, such
carbohydrate-based vaccines can prepare the immune defense
mechanisms in advance of an infection, or to stimulate the
body to protect itself against an existing chronic infection.
This review will give an overview of synthetic or natural
multivalent glycoconjugates that can be used to inhibit the
adhesion of viruses, bacterial toxins, and bacteria to host cells
or to stimulate the innate and adaptive immune systems
against these pathogens. In addition to the pioneering work
of several groups mainly from North America,7,17,25,60,61 this
field is currently flourishing in Europe, and this review is aimed
at giving an overview of this very active domain.
2. Multivalent glycoconjugates against
viral infection
2.1 Targeting DC-SIGN uptake by dendritic cells
Among pathogens, human immunodeficiency virus (HIV) repre-
sents one of the big challenges of current basic and medical
research. Attempts to generate eﬀective microbicides have failed,
so that integrated systems and new strategies are needed in order
to prevent or block the viral infection. Multivalent glycoconjugates
can be utilized in novel vaccine approaches (see Section 6.2.1) or
as inhibitors of first step of infection. One of themain pathways of
HIV infection is mediated by antigen-presenting cells (APC) at the
mucosal endothelium. The high-mannose glycans of envelope
glycoprotein gp120 promote HIV infection by interaction with the
C-type lectin DC-SIGN (dendritic cell-specific ICAM 3-grabbing
non-integrin) expressed on dendritic cells.62 Dendritic cells,
a main group of APC, migrate to the lymph nodes where
they eﬃciently transfer the virus by so-called trans-infection
to T lymphocytes where viral replication occurs. Mimicking the
surface of the virus is a strategy for designing carbohydrate-
based antiviral agents against HIV and Ebola infections.
Glycodendritic compounds have been used as tools to study
and to interfere with infectious processes in which DC-SIGN is
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involved with the aim to develop new antiviral drugs and
immune modulators.63 The conjugation of glycomimetics to
dendritic compounds has provided multivalent compounds
with interesting antiviral activity. IC50s in the low nanomolar
range have been obtained in biological assays using pseudo-
typed Ebola viral particles.64 Also, these compounds present
very good activity as inhibitors of HIV trans-infection of
T-cells, a more relevant infection model where DC-SIGN is
implicated.65,66
Glycodendritic structures have also been prepared recently
using a convergent approach with extensive use of the Cu(I)
catalyzed azide–alkyne cycloaddition (CuAAC) reaction also
known as ‘‘click’’ chemistry (Fig. 1). In this new strategy, first
and second generation glycodendrons have been prepared
conveniently functionalized for further conjugation on diﬀerent
scaﬀolds including a fullerene molecule or a virus-like particle
protein.52,67
The new glycodendritic compounds display a wide variety of
valencies and spatial presentation of carbohydrate ligands. The
glycodendrofullerenes (e.g., 1) prepared using this strategy are
soluble under physiological conditions and present a very low
cellular toxicity. The globular disposition of carbohydrates on
this spherical scaﬀold provides an interesting multivalent
system which allows the carbohydrates to be recognized by
lectins in a multivalent manner. Antiviral activity of these
compounds using pseudotyped Ebola viral particles is in the
micromolar range.52,67
In another attempt to mimic the cluster presentation of
high-mannose-type glycans on the HIV envelope, gold nano-
particles biofunctionalized with oligomannosides (manno-
GNPs, 3a–3d, Fig. 2) of gp120 high-mannose type glycans have
been prepared and tested as anti-HIV agents. These manno-
GNPs inhibited the DC-SIGN/gp120 binding in the micro- to
nanomolar range, while the corresponding monovalent oligo-
mannosides required millimolar concentrations, as measured
by surface plasmon resonance (SPR) experiments.68 Further-
more, manno-GNPs were able to inhibit the DC-SIGN-mediated
HIV trans-infection of human activated peripheral blood mono-
nuclear cells at nanomolar concentrations in an experimental
setting, which mimics the natural route of virus transmission
from dendritic cells to T lymphocytes.69
2.2 Interfering with galectin attachment in lymph nodes
Galectins are lectins with aﬃnity for b-galactosides which
are involved in self/nonself recognition. Galectins from both
invertebrates and vertebrates recognize a variety of viral and
bacterial pathogens and protozoan parasites.70 Galectin-1 is
abundant in thymus and lymph nodes and promotes HIV-1
infection by facilitating virus attachment to the host cell surface
glycan.71 Given that this lectin is directly involved in pathogen
recognition, it could provide a strategy for disrupting the
galectins in virus–host invasion. Host galectins also recognize
endogenous glycans on the host cell surface, which are impor-
tant for certain necessary developmental and immunological
processes.
Structurally defined bivalent lactose-containing clusters
have been designed for optimal binding to galectins.41,72–74
These compounds were evaluated for binding to the entire set
of adhesion/growth-regulatory galectins from chicken. Diﬀeren-
tial sensitivities were detected between distinct galectin forms
within the chicken series. Two of the bivalent glycoclusters,
4 and 5 (Fig. 3), were identified as sensors for diﬀerent galectin
subtypes. Most pronounced were the selectivities of these two
glycoclusters for the chimera-type galectin (galectin-3).
3. Multivalent glycoconjugates against
bacterial toxins
Cholera, still a life-threatening disease in many parts of the
world, is caused by the cholera toxin (CT) produced by Vibrio
cholerae. This toxin consists of a single disease-causing A-subunit
that is surrounded by five lectin-like B-subunits (CTB). The
B-subunits are responsible for attachment of the toxin to the
intestinal surface by binding to exposed GM1-oligosaccharide
(GM1os) moieties.75 The five B-subunits represent a well-
defined multivalent protein target with binding sites for the
GM1os units spaced ca. 30 Å apart. Polyvalent CT inhibitors
were developed starting from weak ligands, such as galactose.
Huge potency increases (up to 106-fold with IC50 = 40 nM)
compared to that of D-galactose were reported by Fan and
co-workers, who prepared and screened a series of penta- and
decavalent ligands with linkers of various lengths.76
The advent of ‘click’ chemistry in combination with chemo-
enzymatic synthesis of the complex oligosaccharide enabled
the assembly of multivalent versions of the GM1os77 into
glycodendrimers (Fig. 4).78 Divalent compound 7a was almost
10 000 times more potent as an inhibitor of CTB binding to
GM1os than monovalent compound 6. This enhancement in
inhibitory potency is related to the multivalent interactions
between CTB and the divalent compound 7a, as the latter does
not show an enhancement in binding to antibodies that do not
allow multiple interactions.79
An additional increase was observed for tetravalent 8a
(83 000 fold). The most complex glycodendrimer in this study,
octavalent 9a, was 380 000 fold more potent (IC50 = 50 pM and
relative inhibitory potency of 47 500 per GM1os).78 A detailed
study of the mode of action revealed that complex aggregates
between the inhibitor and toxin are formed. These are possible
because of the mismatch between the valencies of the toxin
(five) versus those of the inhibitors (two, four, eight).80
The galactose dendrimers 7b, 8b and 9b are a simplified glyco-
mimetic version of the multivalent GM1 derivatives. The inhibi-
tory potency did suﬀer due to this modification since the relatively
large binding site of the B-subunit remains partly unoccupied
resulting in a lower binding aﬃnity. Nevertheless, multivalency
eﬀects were able to counteract the lower binding aﬃnity of
galactose and the inhibitory potencies of compounds 8b and 9b
were shown to be competitive with the natural GM1os ligand.81
A series of ganglioside mimics, in which the non-interacting
oligosaccharide backbone of GM1os was replaced by an
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appropriate cyclohexanediol, was chosen to reproduce the
topological features of the 3,4-disubstituted galactose residue
(Gal-II) in GM1os.82,83 The divalent presentation of a structurally
simplified second generation mimic 10 on a functionalized
calix[4]arene scaﬀold (Fig. 5) led to a 3800-fold (1900-fold per
sugar mimic) enhancement of CTB aﬃnity, thus reaching the
potency of GM1os itself.84 Although computational studies
show that the divalent ligand 11 could easily span two binding
Fig. 1 (a) Glycodendrofullerene 1 with 36 mannoses; (b) glycodendrimer 2 with 18 mannoses prepared using a CuAAC click reaction.
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sites on cholera toxin, NMR data indicate that the action of this
divalent ligand is likely to involve additional interactions
between the linker and the protein.
4. Multivalent glycoconjugates against
bacterial adhesion to human cells
4.1 Uropathogenic E. coli
4.1.1 FimH. Type 1 fimbriae, or pili, are the most abundant
surface structures both in pathogenic and non-pathogenic
Gram-negative bacteria. Type 1 fimbriae are widely expressed
by E. coli and are used by uropathogenic strains to mediate
attachment to specific niches in the urinary tract.85 Type 1
fimbriae mediate attachment to glycosylated surfaces through
FimH, a mannose-specific lectin located at the tip of pili. FimH
is a two-domain lectin, whose crystal structure has been
solved.85 Since the FimH binding site can accommodate only
one a-mannoside, multivalency eﬀects which have been
observed in the inhibition of type 1 fimbriae-mediated bacterial
adhesion42,86–90 cannot be explained on the basis of the struc-
ture of mannose-specific lectin FimH.
Nevertheless, avidity eﬀects have been frequently observed
with a variety of multivalent mannose-containing glycomimetics,
like 12–14 (Fig. 6a–c). Such avidity can originate from statistical
eﬀects arising from (i) a higher concentration of mannose in
the proximity of the carbohydrate binding site, (ii) existence of
additional carbohydrate binding sites on the lectin FimH,
or (iii) occurrence of the natural multivalent process, since
fimbriae occur on the bacterial surface in several hundreds of
copies. Thus, mannose-terminated multivalent glycocompounds
have become important to test mannose-specific bacterial
adhesion in a supramolecular context.88,91 Meanwhile, testing
of type 1 fimbriae-mediated bacterial adhesion has been greatly
facilitated by employing GFP-transfected strains.92 Interest-
ingly, adhesion on multivalent glycomaterials can be utilized
for aggregating E. coli and removing them from solution with
the use of appropriate filters. Glyconanodiamonds decorated
with mannose (Fig. 6d) have been shown to be able to clean
bacteria-polluted water.93
Fullerene hexakis-adducts bearing 12 peripheral mannose
moieties (15–20) have been prepared by grafting sugar deriva-
tives onto the fullerene core52 and assayed as inhibitors of
FimH (Fig. 7).88 Dissociation constants in the range of 12 to
95 nM were measured using isothermal titration calorimetry
(ITC), surface plasmon resonance (SPR) and hemagglutina-
tion assays. Most importantly, the number of possible inter-
actions between the multimers and the lectin and the average
binding strength per functional mannose unit could be
measured. Thus, this study demonstrated for the first time that
a globular C60 structure can accommodate up to seven FimH
molecules.
4.1.2 PapG. While type 1 fimbriae terminated with man-
nose specific FimH are involved in lower urinary tract infection,
E. coli presenting P-fimbriae cause bladder infections resulting
in acute pyelonephritis.94 P-fimbriae are terminated by PapG,
a tip-associated adhesin that recognizes the Gala(1-4)Gal
(galabiose) moiety of the globo-series of glycolipids.95 For the
study of the inhibition of this adhesion by oligovalent galabiose
derivatives, a live bacteria-SPR assay was established, in order
to mimic the flow conditions of natural infections.96
Fig. 3 Bivalent glycoclusters 4 (acyclic) and 5 (macrocyclic), identified as sensors for different galectin subtypes.
Fig. 2 Gold nanoparticles 3a–3d bearing high-mannose type glycans
(manno-GNPs) present on HIV envelope glycoprotein gp120 as anti-HIV synthetic
glycoconjugates.
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Synthetic mono- and multivalent galabiose derivatives 21a–d
(Fig. 8) inhibited bacterial adhesion to the coated chip surfaces
in a dose-dependent manner (Table 1). An octavalent galabiose
compound 21d was superior to the tetravalent derivative 21c,
which in turn was a better inhibitor than the monovalent
galabiose derivative 21a. However, the multivalency eﬀect was
Fig. 4 Structures of GM1os- (7a, 8a and 9a) and galactose (7b, 8b and 9b)-based inhibitors of cholera toxin binding.
Fig. 5 Structurally simplified GM1os mimic 10 grafted onto a functionalized calix[4]arene scaffold to give divalent ligand 11.
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much more pronounced in the case of the Streptococcus suis
adhesion when compared to E. coli PapG. On the other hand, a
more significant multivalency eﬀect was observed in the inhi-
bition of the mannose-specific type-1-fimbriated E. coli with
similar multivalent mannose molecules.97 It would appear that
multivalent inhibitors do not reach multiple E. coli adhesin
molecules as eﬀectively as in the case of other bacteria such as
S. suis (Table 1), and therefore the spacing of the binding sites
in the adhesins may diﬀer.
4.2 Lung pathogens
4.2.1 Pseudomonas aeruginosa soluble lectins. Pseudomo-
nas aeruginosa is an opportunistic pathogen associated with
chronic airway infections, especially in cystic fibrosis patients.
This strain synthesizes two lectins, LecA and LecB,98 which play
a prominent role in human infections. It was demonstrated
that solutions of galactose and fucose, that bind to LecA and
LecB, respectively, have a therapeutic eﬀect against P. aeruginosa
pneumonia in mice models99 and cystic fibrosis patients.100
Recently, glycomimetic peptides were identified that had a high
aﬃnity for binding to both LecA and LecB and could inhibit
their ciliotoxic activity.101
LecA (also called PA-IL) is a tetrameric cytotoxic lectin con-
sisting of four subunits of 121 amino acids (12.75 kDa)98,102 with
specificity for a-D-galactose and binding preferentially to Gala-
(1-4)Gal containing globotriaosylceramide Gb3 sphingolipid. The
LecA crystal structure demonstrated the structural basis of the
aﬃnity for galactose monosaccharides with the participation of a
calcium ion in the binding site.103 In addition to its cytotoxicity, it
has been suggested that this lectin contributes to the formation
of bacterial microcolonies and the formation of biofilms.104
Many of multivalent glycoconjugates have been synthesized
for inhibiting the binding of LecA to galactosylated surfaces
(Table 2 and Fig. 9). High-valency compounds such as galacto-
sylated helical poly(phenylacetylene) polymer 29,34 fullerenes
23,51 glyconanoparticles 31,105 or glycodendrimers 32106 are
eﬃcient ligands for inhibition, but their aggregative properties
and the strong resulting precipitation create diﬃculties for
measuring aﬃnity constants. Excellent results were obtained
with calix[4]arenes 28,38,107 calix[6]arenes 26, b-peptoids 25,
porphyrins 27108 and resorcin[4]arenes 22.109 Among these
molecules, the 1,3-alternate conformer of calix[4]arene demon-
strated the most eﬃcient and dramatic increase in aﬃnity.
A chelate-binding mode with two galactose residues interacting
with two neighbouring binding sites in a single LecA tetramer
could be confirmed by the observation of well-defined nano-
metric fibers of lectin–glycocluster complexes through atomic
force microscopy (AFM) study.110
A recent study demonstrated that a divalent ligand 30 with
an appropriate linker was suﬃcient to induce a chelation eﬀect
Fig. 6 Examples of various multivalent glycoconjugates inhibiting type 1 fimbriae-mediated bacterial adhesion. (a) Octopus glycosides 12; (b) glycodendrimer 13; (c)
bifunctional ligand 14 to test multiple binding sites on FimH; (d) glyconanodiamonds to remove pathogenic bacteria from polluted water sources, a sandwich assay is
displayed, utilizing two different bacterial strains.
Fig. 7 Dodecavalent mannofullerenes 15–20 as FimH inhibitors.
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with LecA.111 A rigid spacer was designed based on the alter-
nation of glucose moieties linked at the 1 and 4 positions by a
1,2,3-triazole unit via ‘‘click’’ chemistry. The resulting spacer
was relatively rigid and straight and was linked to galactose
units at both ends. The number of building blocks was varied,
as well as the linker between the spacer and galactose ligand.
This linker was shown to be of great importance and only
compound 30 (Fig. 9) has the appropriate linker-length for
achieving an inhibitory potency increase of 545-fold over a
relevant reference compound.
Potent ligands for lectin LecA have been also obtained by
synthesis of glycopeptide dendrimers GalAG2 33 and GalBG2 34
(Fig. 10).112 Multivalency strongly influenced binding, with the
monovalent and divalent analogs showing much weaker inter-
actions with the lectin. The much stronger binding of the phenyl
galactosides to LecA compared to the thiopropyl-galactosides
was explained by crystallographic analysis of the lectin–
glycopeptide complexes, which revealed a specific interaction
between a histidine residue on the lectin and the phenyl group
Fig. 8 Oligovalent galabiose derivatives.
Table 1 Relative potencies per sugar unit of galabiose derivatives (Fig. 8) in
surface plasmon resonance (SPR) or hemagglutination inhibition (HAI) assays of
E. coli and S. suis adhesion
E. coli (SPR) E. coli (HAI) S. suis (SPR)
Monovalent (21a) 1.0 1.0 1.0
Divalent (21b) 1.3 1.1 6.7
Tetravalent (21c) 1.9 2.0 63
Octavalent (21d) 5.3 4.4 39
Table 2 Multivalent compounds targeted against LecA. b values are calculated versus the monomeric compounds with linkers, unless otherwise stated
Comp. Valency HIA (MIC) ELLA (IC50) SPR (Kd) ITC (Kd) Ref.
aMeGal 1 150 mM 50 mM 106
bMeGal 1 190 mM 94 mM 106
22 4 Haemolysis 0.7 mM, b = 315 Not soluble —/— 109
23 12 0.78 mM, b = 12820 0.040 mM, b = 458 0.367 mM, b = 173 —/— 51
24 4 > 2000 mM —/— 3.5 mM, b = 18 1.8 mM, b = 83 108
25 4 > 2000 mM —/— 2.5 mM, b = 25 0.3 mM, b = 500 108
26 6 63 mM, b = 159 —/— 0.8 mM, b = 80 0.14 mM, b = 1071 108
27 4 63 mM, b = 159 —/— 1.4 mM, b = 45 0.33 mM, b = 454 108
28 4 500 mM, b = 20 —/— 0.5 mM, b = 144 0.176 mM, b = 852 38
29 Polymer 9 mM —/— —/— 4.12 mM 34
30 2 —/— 0.22 mM, b = 545 —/— —/— 111
31 67 0.45 mM, b = 100 —/— 33 mM 0.05 mM, b = 2824 105
32 9 —/— —/— —/— 230 nM, b = 409 106
33 4 0.78 mM, b = 4000a —/— —/— 0.1 mM, b = 875 112
a b value calculated with galactose as reference.
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in the ligands, while the thiopropyl side-chain was more
disordered.112
LecB (also called PA-IIL) is a tetramer consisting of four
11.73 kDa subunits with high specificity for L-fucose and a
weaker one for D-mannose.98,102 The LecB crystal structure
revealed the occurrence of two bridging calcium ions in the
binding site. This unique mode of binding is not observed in
other lectins,113 but explains the very high aﬃnity for fucosides
and Lewis a. Although most of the LecB is cytoplasmic, it could
also be detected in the outer membrane, including on the
Fig. 9 Multivalent glycoconjugates 22–33 as LecA high affinity ligands.
Chem Soc Rev Review Article
D
ow
nl
oa
de
d 
on
 1
3/
05
/2
01
3 
19
:0
8:
26
. O
pe
n 
A
cc
es
s A
rti
cl
e.
Pu
bl
ish
ed
 o
n 
19
 D
ec
em
be
r 2
01
2 
on
 h
ttp
://
pu
bs
.rs
c.o
rg
 | d
oi:
10.
103
9/C
2C
S3
540
8J
View Article Online
4718 Chem. Soc. Rev., 2013, 42, 4709--4727 This journal is c The Royal Society of Chemistry 2013
surface of biofilm cells, from which it can be released by
application of L-fucose.114 It has recently been hypothesized
that LecB undergoes transient N-glycosylation that could play a
role in the secretion mechanism.115 The search for a putative
binding partner led to the proposal of outer membrane
protein OprF which is a nonspecific, weakly cation-selective
porin channel protein. LecB may mediate the adhesion of
P. aeruginosa cells to receptors that are located on its surface
and facilitate biofilm formation, thereby promoting coloniza-
tion of host tissues.
The search for high aﬃnity ligands for LecB initiated the
synthesis of several classes of fucose-containing compounds
(Table 3 and Fig. 11) based on calixarene 35,116 pentaerythritol
39117 or peptide dendrimer 36–38 scaﬀolds. Compounds have
also been designed for bivalent presentation of aFuc(1- 4)GlcNAc
40,118 and N-fucosyl amides 41.119
Glycopeptide dendrimer ligands for LecB were identified by
screening combinatorial libraries of peptide dendrimers120–122
functionalized with N-terminal C-fucoside residues at the end
of the dendrimer branches. FD2 36 and PA8 37 (Fig. 11) turned
out to be potent ligands for LecB.123,124
Structure–activity relationship studies showed that multi-
valency was important for activity, in particular divalent and
linear peptide analogs of the dendrimers showed strongly
reduced binding at the level of monosaccharides (Table 4).
These studies led to the identification of dendrimer 2G3 38
with 8 fucosyl endgroups as the most potent glycopeptide
dendrimer ligand to LecB. The diastereoisomer D-36 prepared
from D-amino acids was also demonstrated to be a similarly
potent ligand to LecB.125
4.2.2 Inhibition of P. aeruginosa biofilms. One of the key
factors responsible for the virulence and antibiotic resistance of
this pathogen is the formation of biofilms. The development of
therapeutic agents acting on the bacterial biofilm is of utmost
importance. The C-fucosylpeptide dendrimers 36 and D-36
inhibit biofilm formation and eﬃciently disperse established
biofilms of wild type and hospital strains of P. aeruginosa
(Table 4).125,126 Control experiments with LecB-deletion
mutants and dendrimers that are not ligands of LecB showed
that biofilm inhibition required both a potent ligand and LecB
expression, suggesting that the eﬀect was indeed caused by
binding of the ligand to the lectin. The galactosylated peptide
dendrimer such as GalAG0/1/2 33 and GalBG0/1/2 34 (Fig. 10
and Table 4) had strong aﬃnity for LecA and demonstrated
biofilm inhibition and dispersion activity.112 This anti-biofilm
eﬀect mediated by glycopeptide dendrimers was unprecedented
and suggests a new therapeutic approach to control P. aeruginosa
infections.
4.2.3 Burkholderia cenocepacia soluble lectins. Burkholderia
cenocepacia is another opportunistic bacterium causing infec-
tions in patients suﬀering from chronic granulomatous disease
and cystic fibrosis with significant morbidity and mortality.
A family of four soluble lectins has been identified in
B. cenocepacia, each containing at least one domain with strong
sequence similarity with LecB from P. aeruginosa described
above.127 BC2L-A is a small lectin consisting of one dimer of
LecB-like domain that binds mannose and oligomannose-type
N-glycans.127,128
BC2L-A has a strong aﬃnity for a-D-mannosides (Kd of 2 mM
for methyl a-D-mannopyranoside) and mannobioses. Bridging
interaction with the branched trimannoside Mana1-3(Mana1-6)-
Man resulted in the formation of molecular strings as detected
by protein crystallography and AFM. Oligomannose analogs
presenting two mannosides separated by either rigid (42) or
flexible (43) spacer arms were also tested (Fig. 12). Only the
rigid linker yielded high aﬃnity with a fast kinetics of clustering,
while the flexible analog and the trimannoside displayed
moderate aﬃnities and no clustering.128
Micelles formed from mannosylated poly(ethylene oxide)-
b-poly(e-caprolactone) (PEO-b-PCL) diblock copolymer and
nanoparticles of poly(D,L-lactic acid) functionalized with the
same copolymer have also been demonstrated to bind eﬃ-
ciently to BC2L-A.36,129
4.3 Zoonotic bacteria
Streptococcus suis is an important emerging worldwide pig
pathogen and zoonotic agent, which causes meningitis, pneu-
monia and sepsis in pigs and also meningitis in humans.130 An
adhesion activity based on the recognition of glycoconjugates
containing the disaccharide galabiose (i.e. Gala(1-4)Gal) has
been characterized in S. suis. The hydroxyl groups identified to
be involved in the interaction indicate that S. suis adhesin has a
diﬀerent binding mode to galabiose than PapG from uropatho-
genic E. coli. These two adhesins do not display sequence
similarity neither, indicating that they have evolved through
convergent evolution.131
Fig. 10 Structure of glycopeptide dendrimer inhibitors of P. aeruginosa biofilms.
Table 3 Multivalent compounds targeted to LecB. b values are calculated versus
fucose
Comp. Val. ELLA ITC Ref.
aMeFuc 1
0.47 mM
167
35 4 Test biofilm 80% inhibition at 200 mM 116
36 4 0.14 mM, b = 79 —/— 125
37 4 0.11 mM, b = 100 —/— 126
38 8 0.025 mM, b = 440 —/— 168
39 10 0.25 mM, b = 22 —/— 117
40 2 —/— 0.09 mM 118
41 2 —/— 0.62 mM, b = 3 119
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Synthetic derivatives of the receptor disaccharide galabiose
on one hand, or polyvalent dendrimers of galabiose on the
other hand (Fig. 8), have turned out to be exceptionally eﬃcient
inhibitors of S. suis adhesion, both at nanomolar concentra-
tions.132,133 Inhibitors of the adhesion of S. suis to cells have
also been found in natural sources, berries and juices, but their
chemical nature has not yet been identified.134 In the charac-
terization of the adhesion specificities and comparison of
various mono- or oligovalent inhibitors, a live-bacteria applica-
tion of surface plasmon resonance has turned out to be very
useful.96
Due to phase variation, the expression of bacterial adhesins
is not uniform even within a single bacterial strain. Therefore it
may become important to be able to detect specifically bacteria
that express a specific adhesin of potential clinical impact.
Magnetic glyconanoparticles may represent ideal tools for this
purpose. Magnetic beads containing derivatives of galabiose
(Fig. 13) were capable of selecting bacteria in a mixture and
determining their amounts in a luminescence assay.135
Optimisation of the carbohydrate ligand and its multivalent
presentation in appropriate carriers are predicted to further
improve the eﬃciency of the ligand in bacterial adhesion
inhibition and detection.
5. Bacterial cell surface as a target for
anti-infectious agents
5.1 Bacterial LPS: a natural multivalent glycoconjugate
In the cell wall of Gram-negative bacteria, carbohyrates are
mostly conjugated to lipids in the outer membrane, where they
are present in a very high concentration. The bacterial outer
membrane is asymmetric.136 Its external leaflet is almost
entirely constituted of lipopolysaccharides (LPSs) which cover
approximately 75% of the surface giving rise to a multivalent
glycoconjugate surface with very low fluidity and a highly
ordered structure. LPSs are necessary for bacterial viability
and this natural multivalent assembly plays many roles in
Fig. 11 Multivalent glycoconjugates 35–41 as LecB high affinity ligands.
Chem Soc Rev Review Article
D
ow
nl
oa
de
d 
on
 1
3/
05
/2
01
3 
19
:0
8:
26
. O
pe
n 
A
cc
es
s A
rti
cl
e.
Pu
bl
ish
ed
 o
n 
19
 D
ec
em
be
r 2
01
2 
on
 h
ttp
://
pu
bs
.rs
c.o
rg
 | d
oi:
10.
103
9/C
2C
S3
540
8J
View Article Online
4720 Chem. Soc. Rev., 2013, 42, 4709--4727 This journal is c The Royal Society of Chemistry 2013
host–bacterium interactions.136 LPSs are classified as MAMPs
(Microbe-Associated Molecular Patterns) because they are
recognized by the innate immune system. This recognition
takes place through the involvement of specific PRRs (Pathogen
Related Receptors) finely tuned on a MAMP motif, the lipid A
domain.
LPSs isolated or extracted from their natural environment
aggregate in solution due to their amphiphilic nature, resulting
in a supramolecular aggregate which still displays multivalent
features that can be of direct use. Indeed, it has recently
been shown that the HIV protective antibody 2G12 is able to
recognize the LPS produced from Rhizobium radiobacter
Rv3.137 This particular LPS possesses a carbohydrate structure
(Fig. 14) which resembles the epitope on the surface of HIV for
which the antibody is specific. It has been observed that
2G12 interacted with lipooligosaccharides (LOS) only when
the lipid moiety was present, so as to allow formation of a
supramolecular aggregate in water (C. De Castro, personal
communication).
Another interesting example of LPS multivalency relates to
the stabilizing eﬀect on the protein conformation embedded in
Table 4 P. aeruginosa lectin binding and biofilm inhibition by glycopeptide dendrimers
No Structurea Lectin IC50, mM (ELLA)
b KD, mM (ITC)
c r.p./nd Biofilm inhibitione
a-NPF a-(p-Nitrophenyl)-L-fucoside LecB 5.27  0.55 2.1 —
T1 (cFuc-RL)2BRIFV LecB 5  0.45 1.7 n.d.
KT1 37 (cFuc)4(KRL)2BRIFV LecB 0.59  0.059 7.2 n.d.
2G0 cFuc-KPL LecB 5.94  1.24 1.9 n.d.
2G1 (cFuc-KPL)2KFKI LecB 2.7  0.56 2.0 n.d.
37 (cFuc-KPL)4(KFKI)2 KHI LecB 0.14  0.035 20 ++++
D-36 (cFuc-kpl)4(Kfkl)2 Khl LecB 0.66  0.12 4.2 +++
2G3 (cFuc-KP)8(KLF)4(KKI)2KHI LecB 0.025  0.005 55 n.d.
NPG p-Nitrophenyl b-D-galactopyranoside LecA 14.1  0.2 6.2 —
GalAG0 GalA-KPL LecA 4.2  0.9 21 +
GalAG1 (GalA-KPL)2KFKI LecA 0.5  0.2 91 ++
GalAG2 33 (GalA-KPL)4(KFKI)2KHI LecA 0.1  0.01 220 +++
GalBG0 GalB-KPL LecA 51.5  6.7 1.7 +
GalBG1 (GalB-KPL)2KFKI LecA 2.1  1.0 21 ++
GalBG2 34 (GalB-KPL)4(KFKI)2KHI LecA 0.4  0.1 60 +++
a Standard peptide notation with N-terminus at left and C-terminus at right. Amino acids are given in one-letter codes, italics indicate branching
diaminoacids, B is L-2,3-diaminopropionic acid, the C-terminus (at right) is carboxamide (CONH2) in all cases. See also Fig. 10 for exemplification
of the topology and the structure of the glycoside groups C-Fuc, GalA and GalB. b Enzyme-linked lectin assay. c Isothermal titration calorimetry.
d r.p./n is the relative potency compared to the free sugar (L-fucose or D-galactose) per glycoside group. e Biofilm inhibition measured with the steel
coupon assay at 50 mM. n.d. = not determined, — = no inhibition, + = less than 20% inhibition, ++ = 30 to 50% inhibition, +++ = up to 90%
inhibition, ++++ = 100% inhibition.
Fig. 12 Divalent mannosylated compounds as ligands of BC2L.
Fig. 13 Use of galabiose-functionalized magnetic beads for identifying and
isolating S. suis bacteria.
Fig. 14 Structure of the LPS from Rhizobium radiobacter Rv3. The area in the
box displays strong structural similarity with the epitope recognized from the
mAb 2G12. LA stands for lipid A.
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the membrane. This concept guided the formulation of the
new generation vaccine for Neisseria meningitidis group B
(MenB),138 which is the causative agent of meningitis. The
strain belonging to group B is the only member within its
species for which the synthesis of a synthetic glycoprotein
vaccine has not been successful so far as its capsular poly-
saccharide is not immunogenic. The current MenB vaccine is a
vesicle prepared from fragments of the bacterial membrane;
the antigenicity mainly arises from a selected pool of Neisseria
proteins embedded in this artificial membrane, in which
LPSs are thought to work as a multivalent glycoconjugate that
stabilises the vesicle.
Given the high biological importance of LPSs as natural
multivalent glycoconjugates in the elicitation/suppression of
eukaryotic immunity, the structural and supramolecular study
of such molecules plays an important role. In an attempt to
create a ‘‘non-natural’’ LPS multivalent surface, these mole-
cules have been extracted from diﬀerent microbial sources
and reconstituted in liposomes. The physico-chemical investi-
gation of these systems has been performed by a combined
experimental strategy, which has allowed characterisation at
diﬀerent observation scales, from the morphological to the
micro-structural level.139,140 The next step will be the study of
the elicitation of eukaryotic immunity of such an ‘‘artificial’’
bacterial surface.
5.2 Inhibition of LPS synthesis by multivalent
glycoconjugates
L-Heptosides (L-glycero-D-manno-heptopyranoses) are compo-
nents of the core region of LPS. Since LPS is essential for
bacterial viability, its biosynthesis can be targeted for the
development of novel antibacterial agents. A series of fullerene
hexakis-adducts bearing twelve copies of peripheral sugars
displaying the mannopyranose core structure of bacterial
L-heptosides have been synthesized (Fig. 15). The multimers
were assembled through an eﬃcient CuAAC reaction as the
final step. The final fullerene sugar balls were assayed as
inhibitors of heptosyltransferase WaaC, the glycosyltransferase
catalyzing the incorporation of the first L-heptose into LPS.
Interestingly, the inhibition of the final molecules was found in
the low micromolar range (IC50 value of 7 to 45 mM) while the
corresponding monomeric glycosides displayed high micro-
molar to low millimolar inhibition levels (IC50 always above
400 mM). When evaluated on a ‘‘per-sugar’’ basis, these inhi-
bition data showed that, in each case, the average aﬃnity of a
single glycoside of the fullerenes towards WaaC was signifi-
cantly enhanced when displayed as a multimer, thus demon-
strating an unexpected multivalent eﬀect.141 To date, such a
multivalent mode of inhibition had never been evidenced with
glycosyltransferases.
5.3 Exploitation of bacterial S-layers as a natural multivalent
glycan display system
Natural molecular self-assembly systems are prime candidates
for use in nanobiotechnology. Crystalline-cell surface (S-) layers
of prokaryotic organisms are very potent self-assembly systems,
which can be used in bottom-up processes as a patterning
element for the multivalent display of biofunctional epitopes
such as glycans.142
The S-layer system is being exploited for multivalent glycan
display based on the groundbreaking demonstrations that
proteins can be recombinantly equipped with tailor-made
glycosylation in an easily tractable bacterial system such as
Escherichia coli143 and that glycosylation modules from diﬀerent
bacterial sources, including glycoproteins, lipopolysaccharides
or exopolysaccharides, can be combined to achieve functional
glycosylation.144 Using a combination of protein- and glycosylation-
engineering approaches to produce self-assembling S-layer
neoglycoconjugates, the feasibility of this system could be
proven in vitro as well as in vivo, with the latter approach
presenting interesting possibilities for live glycoconjugate delivery
in future antipathogenic therapy.145
In a proof-of-concept study, the S-layer protein SgsE from
Geobacillus stearothermophilus NRS 2004/3a (AF328862) was
used as a matrix for the display of a branched heptasaccharide
from the Campylobacter jejuni protein AcrA as well as for the
E. coli O7 antigen.146 SgsE is a 903-amino acid protein which
aligns in a 2D lattice with oblique (p2) symmetry and which is
naturally O-glycosylated at multiple sites. The SgsE protein was
engineered by including the signal peptide of PelB (pectate
lyase from Erwinia carotovora) for periplasmic targeting.
Furthermore, one of the natural protein O-glycosylation sites
was engineered into an N-glycosylation site to be recognized by
the heterologous oligosaccharyltransferase PglB. In this way,
S-layer neo-glycoproteins could be produced based on plasmid-
encoded glycosylation information for either of the model
glycan structures. The degree of glycosylation of the S-layer
neoglycoproteins after purification from the periplasmic frac-
tion of the E. coli cell factory reached up to 100%. Electron
microscopy revealed that recombinant glycosylation is fully
compatible with the S-layer protein self-assembly system
(Fig. 16). Thus, the S-layer system is a promising strategy
for multivalent glycan display approaches, where strict
(‘‘nanometer-scale’’) control over position and orientation of
the glycan epitopes is desired.
Fig. 15 Multivalent glycosylated fullerenes for inhibition of LPS heptosyltrans-
ferase WaaC.
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6. Glycoconjugate analogs and multivalent
glycoconjugates for immune system
stimulation and vaccine approach
6.1 Glycoconjugate analogs to trigger the innate immunity
Early recognition of invading bacteria by the innate immune
system has a crucial function in antibacterial defense by
triggering inflammatory responses that prevent the spread of
infection and suppress bacterial growth. Toll-like receptor 4
(TLR4), the innate immunity receptor of bacterial endotoxins,
plays a pivotal role in the induction of inflammatory responses.
TLR4 activation by bacterial lipopolysaccharide (LPS) is achieved
by the coordinate and sequential action of three other proteins,
LBP, CD14 and MD-2 receptors, that bind lipopolysaccharide
(LPS) and present it to TLR4 by forming the activated (TLR4-
MD-2-LPS)2 complex (Fig. 17).
147
TLR4 trigger can be remarkably sensitive and robust, stimu-
lating prompt and powerful host defence responses to diﬀerent
species of invading bacteria. However, an excessively potent
host response generates life-threatening syndromes such as
acute sepsis and septic shock. Non-toxic LPSs or lipid A
obtained from non-pathogenic bacteria such as Rhodobacter
capsulatus and Rhodobacter sphaeroides are potent LPS antago-
nists in vitro148 although no molecules usable for pharmaco-
logical treatment for sepsis are not available yet.
Several synthetic molecules capable of modulating TLR4
activity have been developed.149,150 IAXO compounds 47–52,
which include lipidated monosaccharides with an amino group
on the C-6 position of the pyranose ring of D-glucose, were
active in blocking the TLR4 signal in cells and in vivo models
(Fig. 17).151 Their antagonist eﬀect was due to the capacity
of these molecules to displace from CD14 and TLR4-MD-2
complexes.152 These molecules are now commercially available
with the proprietary name of IAXO (Innaxon) as selective small-
molecule inhibitors of the TLR4 signal pathway, and lead
compound IAXO-102 48 is in a preclinical phase as an anti-
sepsis agent. More recently, lipid A analogues such as 53 were
developed with a structure composed of two glucoside units
connected by a linker both units bearing on C-4 an anionic
sulfate group (Fig. 17).153 These compounds have an antagonist
eﬀect if administered together with endotoxin, and a mild
agonist eﬀect if administered alone. In the context of vaccine
adjuvants acting on innate immunity receptors, natural LPS
immobilized on nanoparticles was also demonstrated to have
interesting TLR4 activating properties.154
6.2 Multivalent glycoconjugates in vaccine development
6.2.1 HIV vaccine. An important aspect of HIV glycans is
their role in protecting the underlying protein epitopes from
exposure to the immune response of the host. Nevertheless, the
broadly neutralizing monoclonal antibody 2G12 can target a
cluster of high-mannose oligosaccharides of HIV gp120.155
Moreover, new broadly neutralizing antibodies that are also
carbohydrate-directed have been isolated recently from
patients.156 Mimicking the cluster presentation of oligomanno-
sides expressed at the HIV-1 surface is a strategy for eliciting a
vaccine response. Several groups, including those of Wang,157,158
Wong,159,160 Danishefsky,48,161 and Rappuoli,162 have multi-
merized high mannose-type oligosaccharides on synthetic
Fig. 16 Model of a self-assembled SgsE-neoglycoprotein monolayer periodically
displaying recombinant E. coli O7 antigens with nanometer-scale precision.
Image reconstruction using Cinema 4 is based on a negatively stained prepara-
tion of the S-layer protein self-assembled in solution and on the pdb data of the
glycans generated with Sweet at http://www.glycosciences.de/ (adapted from
ref. 146, Wiley-VCH Weinheim).
Fig. 17 Synthetic lipids with TLR4-modulating activity.
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scaﬀolds in order to mimic the carbohydrate epitope of
2G12. Although most of these systems were able to induce a
carbohydrate-specific immune response in animals, the IgG
antibodies were unable to bind to gp120 or neutralize the virus.
The diﬃculty of eliciting high titers of antibodies against the
2G12 epitope remains a still open challenge in search for
synthetic carbohydrate-based vaccines against HIV.
Together with new studies on the molecular basis of the
interactions between glycans and anti-HIV antibodies, gold
nanoparticles functionalized with oligomannosides (manno-
GNPs, Fig. 2) can oﬀer an alternative in this direction. In order
to gain deeper insights into the interactions between 2G12 and
selected oligomannosides at the molecular level, the structural
and aﬃnity details of the 2G12/oligomannosides interactions
have been studied by saturation transfer diﬀerence NMR
spectroscopy (STD-NMR) and transferred NOE in isotropic
solution.163 It was found that linear oligomannosides show a
single binding mode to 2G12, with the non-reducing terminal
disaccharide Man(a1-2)Man(a1-, making the closest antibody/
oligosaccharide contacts in the bound state. In contrast, a
branched pentamannoside showed two alternate binding
modes involving both ligand arms, contrary to previous X-ray
studies.164 Among the analysed series of ligands, the strongest
2G12 binders were the linear tri- and tetramannosides. This
information is of key importance for the design of synthetic
multivalent gp120 high-mannose mimics for HIV vaccine develop-
ment. Indeed manno-GNPs were able to bind with high aﬃnity
and to interfere with the 2G12/gp120 binding as determined by
SPR-based biosensors and STD-NMR.165 Cellular neutralization
assays with manno-GNPs also demonstrated that GNPs coated
with a linear tetramannoside could block the 2G12-mediated
neutralization of a replication-competent HIV-1 under conditions
that resemble those in which normal serum prevents infection of
the target cell. All these results prove that selected manno-GNPs
could function as an anti-adhesive barrier at an early stage of HIV
infection, but also as synthetic mimics of the 2G12 epitope in the
route of a carbohydrate-based vaccine against HIV.
6.2.2 Streptococcus pneumoniae vaccine. The feasibility of
using gold nanoparticles as carriers has been tested for the
production of a carbohydrate-based vaccine candidate. Gold
GNP 54 coated with a conjugate of the synthetic tetrasaccharide
Galb(1-4)Glcb(1-6)[Galb(1-4)]GlcNAcb(1-, the repeating units of
Streptococcus pneumoniae capsular polysaccharide, and a
T-helper peptide (Fig. 18) were able to induce a carbohydrate-
specific immune response in mice, which resulted in the genera-
tion of functional IgG antibodies against this bacterium.166
7. Conclusions
The recent advances in the synthesis of complex glycomolecules
with controlled topology and valency coupled with the progress
in understanding the importance of protein–carbohydrate
interactions have driven forward the domain of multivalent
glycomolecules. Indeed, these molecules have proven to be very
potent frameworks for binding to a range of glycan receptors,
and therefore have the ability to stimulate, mediate or inhibit a
variety of biological or pathological processes. The diﬀerent
applications of glycocompounds in anti-infectious strategies
should be further developed in the future, with knowledge-
based approaches that take into account the structure of the
protein receptors. Designing multivalent glycoconjugates that
perfectly fit the topology of binding sites will increase their
aﬃnity toward the target, and help in fine-tuning their speci-
ficity. Based on the reports summarized in this review, it
appears that multivalent glycoconjugates are close to be utilised
in anti-adhesive therapies against viral and bacterial infection,
but can are be used to mimic bacterial cell surfaces in order to
stimulate the immune systems.
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